Skip to content
WeighLab
Menu
Ranked #7 · Grade BEditorial review

Ro review

The widest formulary — brand-name and oral access — but opaque compounded pricing means you can't model the value until you're already in the funnel.

Visit Ro Editorial review — no commercial relationship.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Multi-state
Brand-name
Yes

The Index scorecard

Ro scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month74/100
Price Transparency72/100
Nationwide Access85/100
Formulation Options93/100
Clinical Oversight90/100
Contract Flexibility84/100

Where the value is

  • Brand-name access and insurance support
  • Oral options widen the formulary
  • Polished, well-funded platform

The tradeoffs

  • Does not publish compounded pricing up front — a blind spot in any cost model
  • Premium positioning

The bottom line

Best for: People who need brand-name (Wegovy/Zepbound) access or insurance navigation and will accept price opacity for it. The widest formulary — brand-name and oral access — but opaque compounded pricing means you can't model the value until you're already in the funnel.

Ranked #7 of 9 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.

Compare with other providers

All 8 other providers we've modeled, in Cost-Efficiency Index order.

Pricing, states and verification reflect Ro's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Ro's site. Not medical advice; see our disclosure.

← Back to the value leaderboard